Mineral metabolism markers are associated with myocardial infarction and hemorrhagic stroke but not ischemic stroke in hemodialysis patients: A longitudinal study

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Tagawa, Miho ^a   Hamano, Takayuki ^b   Nishi, Hiroshi ^b   Tsuchida, Kenji ^b   Hanafusa, Norio ^b   Fukatsu, Atsushi ^c   Iseki, Kunitoshi ^b   Tsubakihara, Yoshiharu ^b  

^a KYOTO KATSURA HOSPITAL   (Japan)

^b Scientific Academic Committee of the Japanese Society for Dialysis Therapy   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERAL; PARATHYROID HORMONE; PHOSPHATE; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE REGISTRY; FEMALE; HEART INFARCTION; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; JAPANESE (PEOPLE); LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; REFERENCE VALUE; ADVERSE EFFECTS; BLOOD; HEMODIALYSIS; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE;

BIOMARKERS; BRAIN ISCHEMIA; CALCIUM; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS; STROKE;

EID: 84916910223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114678     Document Type: Article

References (30)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium 6 phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607-617.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218.
3. Slinin Y, Foley RN, Collins AJ (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16: 1788-1793.
4. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, et al. (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179-1187.
5. Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, et al. (2007) Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int 11: 340-348.
6. Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M, et al. (2008) Effects of serum calcium, phosphorous and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 12: 49-54.
7. Floege J, Kim J, Ireland E, Chazot C, Drueke T, et al. (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 26: 1948-1955.
8. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, et al. (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780.
9. Shoji T, Masakane I, Watanabe Y, Iseki K, Tsubakihara Y, et al. (2011) Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol 6: 1112-1120.
10. Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, et al. (2009) An overview of regular dialysis treatment in Japan (as of 31 December 2007). Ther Apher Dial 13: 457-504.
11. Nakai S, Masakane I, Akiba T, Shigematsu T, Yamagata K, et al. (2008) Overview of regular dialysis treatment in Japan as of 31 December 2006. Ther Apher Dial 12: 428-456.
12. Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4: 643-646.
13. No authors listed (2003) K/DOQI clinical guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 13):: S1-S170.
14. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK (2001) Association of elevated serum PO4, Ca X PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138.
15. Shroff R, Long DA, Shanahan C (2013) Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 24: 179-189.
16. Kumar A, Cannon CP (2009) Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc 84: 917-938.
17. Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, et al. (2009) Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 20: 1504-1512.
18. Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Wittkowski W, et al. (2008) Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 294: F1381-1387.
19. Navarro-González JF, Mora-Fernández C, Muros M, Herrera H, García J (2009) Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. Clin J Am Soc Nephrol 4: 1646-1654.
20. Rashid G, Bernheim J, Green J, Benchetrit S (2007) Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 292: F1215-1218.
21. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, et al. (2003) Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41: 1769-1775.
22. Takase B, Matsushima Y, Uehata A, Ishihara M, Kurita A (2008) Endothelial dysfunction, carotid artery plaque burden, and conventional exercise-induced myocardial ischemia as predictors of coronary artery disease prognosis. Cardiovasc Ultrasound 6: 21.
23. Onoyama K, Kumagai H, Miishima T, Tsuruda H, Tomooka S, et al. (1986) Incidence of strokes and its prognosis in patients on maintenance hemodialysis. Jpn Heart J 27: 685-691.
24. Toyoda K, Fujii K, Fujimi S, Kumai Y, Tsuchimochi H, et al. (2005) Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis 45: 1058-1066.
25. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, et al. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032.
26. Seliger SL, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, et al. (2003) Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 14: 2623-2631.
27. Kawamura M, Fijimoto S, Hisanaga S, Yamamoto Y, Eto T (1998) Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis 31: 991-996.
28. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, et al. (2010) Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77: 1098-1106.
29. Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20: 2223-2233.
30. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, et al. (2003) Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14: 3270-32.